Investors Buy Large Volume of Climb Bio Call Options (NASDAQ:CLYM)

Climb Bio, Inc. (NASDAQ:CLYM) was the target of some unusual options trading activity on Wednesday. Investors purchased 3,024 call options on the company. This represents an increase of approximately 740% compared to the average daily volume of 360 call options.

Climb Bio News Roundup

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Phase 2 progress in China: Climb Bio advanced its Phase 2 trial in China, a development that may strengthen confidence in its pipeline. However, the accompanying analysis questioned whether this progress is already reflected in the valuation. Climb Bio Advances Phase 2 Trial In China, Is The Valuation Already Priced In?
• Positive Sentiment: More favorable earnings outlook: HC Wainwright raised its estimated loss for fiscal 2026 to $0.76 per share from $0.93, narrowed its projected Q3 loss to $0.20 from $0.23, and reduced its Q4 loss estimate to $0.19 from $0.22. Its FY2027 loss estimate also improved slightly to $0.98 from $0.99 per share.
• Positive Sentiment: Buy rating and upside target: HC Wainwright reiterated a “Buy” rating and a $24 price target, implying meaningful potential upside from recent trading levels. The improved forecasts are more optimistic than some consensus estimates.
• Neutral Sentiment: Heavy call-option activity: Traders purchased 3,024 call options on August 26, roughly 740% above the average volume. This indicates elevated speculative interest and may reflect bullish expectations, although options activity alone does not confirm a sustained move higher.
• Negative Sentiment: Unusually large put buying: Investors purchased 7,091 put options on August 27, approximately 1,046% above typical volume. The sharp increase points to heightened downside hedging or bearish speculation and likely contributed to pressure on CLYM.

Analyst Upgrades and Downgrades

Several analysts recently commented on CLYM shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Climb Bio in a research note on Friday, July 17th. Royal Bank Of Canada assumed coverage on shares of Climb Bio in a report on Monday, August 3rd. They issued an “outperform” rating and a $23.00 target price for the company. Wall Street Zen upgraded shares of Climb Bio from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. HC Wainwright lifted their price target on shares of Climb Bio from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Monday. Finally, BTIG Research boosted their price target on Climb Bio from $19.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, June 11th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $23.08.

Institutional Trading of Climb Bio

Large investors have recently modified their holdings of the business. California State Teachers Retirement System purchased a new position in Climb Bio during the second quarter worth $82,000. Braidwell LP boosted its stake in shares of Climb Bio by 102.6% during the second quarter. Braidwell LP now owns 3,099,027 shares of the company’s stock valued at $40,411,000 after acquiring an additional 1,569,352 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Climb Bio during the second quarter valued at $1,262,000. Bank of America Corp DE purchased a new stake in Climb Bio during the 2nd quarter worth about $335,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Climb Bio during the 2nd quarter worth about $10,727,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Climb Bio Stock Down 6.3%

NASDAQ:CLYM opened at $15.06 on Friday. The company has a market capitalization of $865.05 million, a PE ratio of -18.14 and a beta of 0.08. Climb Bio has a 52-week low of $1.54 and a 52-week high of $18.33. The stock has a fifty day simple moving average of $13.76 and a 200-day simple moving average of $10.44.

Climb Bio (NASDAQ:CLYM) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. As a group, equities analysts anticipate that Climb Bio will post -0.82 earnings per share for the current year.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.